|
1
|
Mayer-Davis EJ, Lawrence JM, Dabelea D,
Divers J, Isom S, Dolan L, Imperatore G, Linder B, Marcovina S,
Pettitt DJ, et al SEARCH for Diabetes in Youth Study, : Incidence
trends of type 1 and type 2 diabetes among youths, 2002–2012. N
Engl J Med. 376:1419–1429. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
John S: Complication in diabetic
nephropathy. Diabetes Metab Syndr. 10:247–249. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keri KC, Samji NS and Blumenthal S:
Diabetic nephropathy: Newer therapeutic perspectives. J Community
Hosp Intern Med Perspect. 8:200–207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Magee C, Grieve DJ, Watson CJ and Brazil
DP: Diabetic nephropathy: A tangled web to unweave. Cardiovasc
Drugs Ther. 31:579–592. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Donate-Correa J, Martín-Núñez E,
Muros-de-Fuentes M, Mora-Fernández C and Navarro-González JF:
Inflammatory cytokines in diabetic nephropathy. J Diabetes Res.
2015:9484172015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yeo ES, Hwang JY, Park JE, Choi YJ, Huh KB
and Kim WY: Tumor necrosis factor (TNF-alpha) and C-reactive
protein (CRP) are positively associated with the risk of chronic
kidney disease in patients with type 2 diabetes. Yonsei Med J.
51:519–525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen S, Xie S, He W, Wei D, Li S and Chen
W: Beneficial effect of beraprost sodium plus aspirin in the
treatment of acute ischemic stroke. Med Sci Monit. 23:4401–4407.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanaka S, Akaike T, Wu J, Fang J, Sawa T,
Ogawa M, Beppu T and Maeda H: Modulation of tumor-selective
vascular blood flow and extravasation by the stable prostaglandin
12 analogue beraprost sodium. J Drug Target. 11:45–52. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li S, Wang Y, Chen L, Wang Z, Liu G, Zuo
B, Liu C and Sun D: Beraprost sodium mitigates renal interstitial
fibrosis through repairing renal microvessels. J Mol Med (Berl).
97:777–791. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang XF, Zhang BH, Lu XQ and Wang P:
Beraprost sodium, a stable analogue of PGI2, inhibits the
renin-angiotensin system in the renal tissues of rats with chronic
renal failure. Kidney Blood Press Res. 43:1231–1244. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei W, An XR, Jin SJ, Li XX and Xu M:
Inhibition of insulin resistance by PGE1 via autophagy-dependent
FGF21 pathway in diabetic nephropathy. Sci Rep. 8:92018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang JZ, Kang XJ, Gao Y, Zheng YY, Wu TT,
Li L, Liu F, Yang YN, Li XM, Ma YT, et al: Efficacy of alprostadil
for preventing of contrast-induced nephropathy: A meta-analysis.
Sci Rep. 7:10452017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goya K, Otsuki M, Xu X and Kasayama S:
Effects of the prostaglandin I2 analogue, beraprost sodium, on
vascular cell adhesion molecule-1 expression in human vascular
endothelial cells and circulating vascular cell adhesion molecule-1
level in patients with type 2 diabetes mellitus. Metabolism.
52:192–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qin L, Qin W, Wang J and Lin L: Combined
treatment of diabetic nephropathy with alprostadil and calcium
dobesilate. Exp Ther Med. 14:5012–5016. 2017.PubMed/NCBI
|
|
15
|
Gabir MM, Hanson RL, Dabelea D, Imperatore
G, Roumain J, Bennett PH and Knowler WC: Plasma glucose and
prediction of microvascular disease and mortality: Evaluation of
1997 American Diabetes Association and 1999 World Health
Organization criteria for diagnosis of diabetes. Diabetes Care.
23:1113–1118. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shaw JE, Sicree RA and Zimmet PZ: Global
estimates of the prevalence of diabetes for 2010 and 2030. Diabetes
Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanabe K, Maeshima Y, Sato Y and Wada J:
Antiangiogenic therapy for diabetic nephropathy. BioMed Res Int.
2017:57240692017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Atkins RC: The epidemiology of chronic
kidney disease. Kidney Int Suppl. 94:S14–S18. 2005. View Article : Google Scholar
|
|
19
|
Shima A, Miyamoto M, Kubota Y, Takagi G
and Shimizu W: Beraprost sodium protects against diabetic
nephropathy in patients with arteriosclerosis obliterans: A
prospective, randomized, open-label study. J Nippon Med Sch.
82:84–91. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo C, Li T, Zhang C, Chen Q, Li Z, Liu J
and Wang Y: Therapeutic effect of alprostadil in diabetic
nephropathy: Possible roles of angiopoietin-2 and IL-18. Cell
Physiol Biochem. 34:916–928. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mathiesen ER, Hommel E, Olsen UB and
Parving HH: Elevated urinary prostaglandin excretion and the effect
of indomethacin on renal function in incipient diabetic
nephropathy. Diabet Med. 5:145–149. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Wan JX, Jiang DW, Fu BB, Cui J and
Li GF: Clinical efficacy and safety of sequential treatment with
alprostadil and beraprost sodium for chronic renal failure induced
by chronic glomerulonephritis. Nan Fang Yi Ke Da Xue Xue Bao.
33:1521–1524. 2013.(In Chinese). PubMed/NCBI
|
|
23
|
Santos RA, Ferreira AJ, Verano-Braga T and
Bader M: Angiotensin-converting enzyme 2, angiotensin-(1–7) and
Mas: New players of the renin-angiotensin system. J Endocrinol.
216:R1–R17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Raebel MA: Hyperkalemia associated with
use of angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers. Cardiovasc Ther. 30:e156–e166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miyamori I, FitzGerald GA, Brown MJ and
Lewis PJ: Prostacyclin stimulates the renin angiotensin aldosterone
system in man. J Clin Endocrinol Metab. 49:943–944. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Navarro-González JF and Mora-Fernández C:
The role of inflammatory cytokines in diabetic nephropathy. J Am
Soc Nephrol. 19:433–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Navarro-González JF, Jarque A, Muros M,
Mora C and García J: Tumor necrosis factor-alpha as a therapeutic
target for diabetic nephropathy. Cytokine Growth Factor Rev.
20:165–173. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu CP and Yu ZJ: Study on
L-ornithine-L-aspartate in the treatment of acute-on-chronic liver
failure. Zhonghua Gan Zang Bing Za Zhi. 19:63–64. 2011.(In
Chinese). PubMed/NCBI
|
|
29
|
Deng J, Feng J, Liu T, Lu X, Wang W, Liu
N, Lv Y, Liu Q, Guo C and Zhou Y: Beraprost sodium preconditioning
prevents inflammation, apoptosis, and autophagy during hepatic
ischemia-reperfusion injury in mice via the P38 and JNK pathways.
Drug Des Devel Ther. 12:4067–4082. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ho Y: Glucose metabolism and diabetes.
Patient-Specific Controller for an Implantable Artificial Pancreas.
Springer; Singapore: pp. 11–17. 2019, View Article : Google Scholar
|
|
31
|
Nitulescu GM, Van De Venter M, Nitulescu
G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Grădinaru D, Tsatsakis
A, Tsoukalas D, et al: The Akt pathway in oncology therapy and
beyond (Review). Int J Oncol. 53:2319–2331. 2018.PubMed/NCBI
|
|
32
|
Takenaga M, Ishihara T, Niimi J, Hamaguchi
A, Asano T, Tsuchiya R, Ohta Y, Mizushima T and Yudoh K: Nano PGE1
enhances phosphorylation of ERK1/2 and Akt to promote recovery from
motor dysfunction and muscle atrophy induced by sciatic nerve
injury. Preprints 2019. https://www.preprints.org/manuscript/201901.0250/v1
|
